Advanced search
Publication Cover
Pain Management Volume 2, 2012 - Issue 5
Submit an article Journal homepage
44
Views
0
CrossRef citations to date
0
Altmetric
Review

Tapentadol Extended-Release: A Recent Addition to our Analgesic Armamentarium

Richard B Silverman1 Department of Anesthesiology, Perioperative Medicine & Pain Management, Miller School of Medicine, University of Miami, Miami, FL33136, USA
,
Keith A Candiotti1 Department of Anesthesiology, Perioperative Medicine & Pain Management, Miller School of Medicine, University of Miami, Miami, FL33136, USA;1 Department of Anesthesiology, Perioperative Medicine & Pain Management, Miller School of Medicine, University of Miami, Miami, FL33136, USACorrespondence[email protected]
&
Melvin C Gitlin1 Department of Anesthesiology, Perioperative Medicine & Pain Management, Miller School of Medicine, University of Miami, Miami, FL33136, USA
Pages 451-456 | Published online: 09 Oct 2012

References

  • Nuceynta® ER, package insert. Janssen Pharmaceuticals, PR, USA.
  • Vadivelu N , TimchencoA, HuangY, SinatraR. Tapentadol extended-release for treatment of chronic pain a review. J. Pain Res.4 , 211–218 (2011).
  • Tapentadol (Nucynta) – a new analgesic. Med. Lett. Drugs Ther.51(1318) , 61–62 (2009).
  • Frampton JE . Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs70(13) , 1719–1743 (2010).
  • Candiotti KA , GitlinMC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr. Med. Res. Opin26(7) , 1677–1684 (2010).
  • Power I . An update on analgesics. Br. J. Anaesth.107(1) , 19–24 (2011).
  • Lewis KS , HannNN. Tramadol: a new centrally acting analgesic. Am. J. Health Syst. Pharm.54(6) , 643–652 (1997).
  • Lee CR , McTavishD, SorkinEM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and the therapeutic potential in acute and chronic pain states. Drugs46(2) , 313–340 (1993).
  • Etropolski MS , OkamotoA, ShapiroDY, RaushkolbC. Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician13(1) , 61–70 (2010).
  • Daniels SE , UpmalisD, OkamotoA, LangeC, HaeusslerJ. A randomized, double-blind, Phase III study comparing multiple doses of tapentadol IR, oxycodone IR and placebo for postoperative (bunionectomy) pain. Curr. Med. Res. Opin25(3) , 765–776 (2009).
  • Kleiner R , LangeC, SteupA, BlackP, GoldbergJ, DesjardinsP. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth. Analg.107(6) , 2048–2055 (2008).
  • Afilalo M , EtropolskiMS, KuperwasserB et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee; a randomized, double-blind, placebo- and active-controlled Phase III study. Clin. Drug Investig. 30(8) , 489–505 (2010).
  • Wade WE , SpruillWJ. Tapentadol hydrochloride; a centrally acting oral analgesic. Clin. Ther.31(12) , 2804–2818 (2009).
  • Froiu D , SinatraRS. Oral and parental analgesics. In: The Essence of Analgesia and Analgesics. Sinatra J, Michael Watkins-Pitchford J (Eds). Cambridge University Press, Cambridge, UK, 143–147 (2010).
  • Tzschentke TM , ChristophT, KogalB et al. (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-metheyl-propyl)-phenol hydrochloride (tapentadol HCL): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J. Pharmacol. Exp. Ther. 323(1) , 256–276 (2007).
  • Tzschentke TM , FolgeringJHA, FlikG, De Vry J. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Neurosci. Lett.507 , 151–155 (2012).
  • Tzschentke TM , ChrisophT, SchroderW, et al. Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview. Schmerz25 , 19–25 (2011).
  • Schwartz S , EtropolskiM, ShapiroDY, OkamotoA, HaeusslerJ, RauschkolbC. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr. Med. Res. Opin27(1) , 151–162 (2011).
  • Terlinden R , KogelBY, EnglbergerW, TzschentkeTM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find. Exp. Clin. Pharmacol.32(1) , 31–38 (2010).
  • Smith JW , KleideiterE, BrettM et al. Pharmacokinetics of tapentadol in subjects with varying degrees of renal impairment. Presented at: 39th Annual Meeting of the American College of Clinical Pharmacology. Baltimore, MD, USA, September 2010 (Poster).
  • Hartick CT , RozekRJ. Tapentadol in pain management; a mu receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs25(5) , 359–370 (2011).
  • Xu XS , SmitJW, LinR, StuyckensK, TerlindenR, NandyP. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin. Pharmacokinet.49(10) , 671–682 (2010).
  • Cepeda MS , SuttonA, WeinsteinR, KimM. Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. Clin. J. Pain28(1) , 8–13 (2012).
  • Wild JE , GrondS, KuperwasserB. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract.10(5) , 416–427 (2010).
  • Buynak R , ShapiroDY, OkamotoA et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 11(11) , 1787–1804 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.